ID: ALA3917688

Max Phase: Preclinical

Molecular Formula: C27H34N4O7S

Molecular Weight: 558.66

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(S(=O)(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(OC(=O)N3CCN(C)CC3)cc2)C(=O)O)cc1

Standard InChI:  InChI=1S/C27H34N4O7S/c1-19-5-11-22(12-6-19)39(36,37)31-13-3-4-24(31)25(32)28-23(26(33)34)18-20-7-9-21(10-8-20)38-27(35)30-16-14-29(2)15-17-30/h5-12,23-24H,3-4,13-18H2,1-2H3,(H,28,32)(H,33,34)/t23-,24-/m0/s1

Standard InChI Key:  LTENJGUZJGMMFE-ZEQRLZLVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 558.66

Molecular Weight (Monoisotopic): 558.2148

AlogP: 1.71

#Rotatable Bonds: 8

Polar Surface Area: 136.56

Molecular Species: ACID

HBA: 7

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 2.77

CX Basic pKa: 6.85

CX LogP: -0.40

CX LogD: -0.86

Aromatic Rings: 2

Heavy Atoms: 39

QED Weighted: 0.50

Np Likeness Score: -1.15

References

1.  (2003)  Alpha-9 integrin antagonists and anti-inflammatory compositions therof, 

Source

Source(1):

• Patent Bioactivity Data